Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 107, Issue , 2016, Pages 30-42

  Rice, Harry B ^a   Bernasconi, Aldo ^a   Maki, Kevin C ^b   Harris, William S ^c,d,e   von Schacky, Clemens ^f,g   Calder, Philip C ^h,i  

^a Global Organization for EPA and DHA Omega 3s (GOED)   (United States)

^b Midwest Center for Metabolic and Cardiovascular Research   (United States)

^c Health Diagnostic Laboratory Inc   (United States)

^d UNIVERSITY OF SOUTH DAKOTA   (United States)

^e OmegaQuant Analytics   (United States)

^f UNIVERSITY OF MUNICH   (Germany)

^g Omegametrix GmbH   (Germany)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiovascular disease; Design; Docosahexaenic; Eicosapentaenoic; Omega 3

Indexed keywords

DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PLACEBO; CARDIOVASCULAR AGENT;

ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DATA ANALYSIS; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG RESEARCH; HEART PROTECTION; HUMAN; INFORMATION PROCESSING; META ANALYSIS (TOPIC); METHODOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SAMPLE SIZE; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; WORKSHOP; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENT; STATISTICAL ANALYSIS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DATA INTERPRETATION, STATISTICAL; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84962052424     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2016.01.003     Document Type: Article

References (107)

1. Galan P., Kesse-Guyot E., Czernichow S., et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010, 341:c6273.
2. Kromhout D., Giltay E.J., Geleijnse J.M., Alpha Omega Trial Group n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 2010, 363:2015-2026.
3. Rauch B., Schiele R., Schneider S., et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline- adjusted therapy after myocardial infarction. Circulation 2010, 122:2152-2159.
4. ORIGIN Trial Investigators, Bosch J., Gerstein H.C., et al. n-3 fatty acids and cardiovascular outcomes in pateients with dysglycemia. N. Engl. J. Med. 2012, 367:309-318.
5. Macchia A., Grancelli H., Varini S., et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. J. Am. Coll. Cardiol. 2013, 61:463-468.
6. Risk and Prevention Study Collaborative Group, Roncaglioni M.C., Tombesi M., et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 2013, 368:1800-1808.
7. Strand E., Pedersen E.R., Svingen G.F., et al. Dietary intake of n-3 long-chain polyunsaturated fatty acids and risk of myocardial infarction in coronary artery disease patients with or without diabetes mellitus: a prospective cohort study. BMC Med. 2013, 11:216.
8. Burr M.L., Fehily A.M., Gilbert JF J.F., et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989, 334:757-761.
9. GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISS-Prevenzione trial. Lancet 1999, 354:447-455.
10. Yokoyama M., Origasa H., Matsuzaki M., et al. Japan EPA lipid intervention study (JELIS) Investigators, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
11. GISSI-HF Investigators, Tavazzi L., Maggioni A.P., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
12. Harris W.S., Kris-Etherton P.M., Harris K.A. Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr. Atheroscler. Rep. 2008, 10:503-509.
13. Rice J. Mathematical Statistics and Data Analysis 1995, Duxbury Press, Belmont, CA, Chapter 9. 2nd edition.
14. Guo J.W., Sward K.A., Beck S.L., Staggers N. Quality of reporting randomized control trials in cancer nursing research. Nurs. Res. 2014, 63:26-35.
15. Begg C., Cho M., Eastwood S., et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996, 276:637-639.
16. Turner L., Shamseer L., Altman D.G., et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst. Rev 2012, 11. MR0000030.
17. Enns J.E., Yeganeh A., Zarychanski R., et al. The impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysis. BMC Cardiovasc. Disord. 2014, 14:70.
18. Leng G.C., Lee A.J., Fowkes F.G., et al. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. Clin. Nutr. 1998, 17:265-271.
19. Ishikawa Y., Yokoyama M., Saito Y., et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circ. J. 2010, 74:1451-1457.
20. EFSA Panel on Dietetic Products Nutrition and allergies, scientific opinion related to the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J. 2012, 10:2815. http://www.efsa.europa.eu/en/efsajournal/doc/2815.pdf.
21. Norwegian Scientific Committee for Food Safety (VKM) Evaluation of negative and positive health effects of n-3 fatty acids as constituents of food supplements and fortified foods 2011, Opinion of the Steering Committee of the Norwegian Scientific Committee for Food Safety, Available online at. http://www.vkm.no/dav/c7a41adb79.pdf.
22. Papanikolau Y., Brooks J., Reider C., Fulgoni V.L. U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational data from NHANES 2003-2008. Nutr. J. 2014, 13:31.
23. Environmental Protection Agency. Intake of Fish and Shellfish, in: Exposure Factors Handbook, 2011, Online at. http://www.epa.gov/ncea/efh/pdfs/efh-chapter10.pdf.
24. Mozaffarian D., Rimm E.B. Fish intake, contaminants and human health: evaluating the risks and benefits. JAMA 2006, 296:1885-1890.
25. James M.J., Sullivan T.R., Metcalf R.G., Cleland L.G. Pitfalls in the use of randomised controlled trials for fish oil studies with cardiac patients. Br. J. Nutr. 2014, 112:812-820.
26. Kwak S.M., Myung S.K., Lee Y.J., Seo H.G. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch. Intern. Med. 2012, 172:686-694.
27. Bang H.O., Dyerberg J., Hjoorne N. The composition of food consumed by Greenland Eskimos. Acta. Med. Scand. 1976, 200:69-73.
28. Bang H.O., Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. Adv. Nutr. Res. 1980, 2:1-22.
29. Dyerberg J., Bang H.O., Stoffersen E., Moncada S., Vane J.R. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet 1978, 2:117-119.
30. Leaf A. Historical overview of n-3 fatty acids and coronary heart disease. Am. J. Clin. Nutr. 2008, 87:1978S-1980S.
31. Simon J.A., Fong J., Bernert J.T., Browner W.S. Serum fatty acids and the risk of stroke. Stroke 1995, 26:778-782.
32. Siscovick D.S., Raghunathan T.E., King I., et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995, 1:1363-1367.
33. He K., Song Y., Daviglus M.L. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004, 109:2705-2711.
34. Marchioli R., Barzi F., Bomba E., GISSI-Prevenzione Investigators, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105:1897-1903.
35. Saravanan P., Davidson N.C., Schmidt E.B., Calder P.C. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010, 376:540-550.
36. Rizos E.C., Ntzani E.E., Bika E., Kostapanos M.S., Elisaf M.S. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308:1024-1033.
37. Kotwal S., Jun M., Sullivan D., Perkovic V., Neal B. Omega-3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ. Cardiovasc. Qual. Outcomes 2012, 5:808-818.
38. Chowdhury R., Warnakula S., Kunutsor S., et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann. Intern. Med. 2014, 160:398-406.
39. Wen Y.T., Dai J.H., Gao Q. Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Nutr. Metab. Cardiovasc. Dis. 2014, 24:470-475.
40. Itakura H., Yokoyama M., Matsuzaki M., JELIS Investigators, et al. Relationships between plasma fatty acid composition and coronary artery disease. J. Atheroscler. Thromb. 2011, 18:99-107.
41. Mozaffarian D., Lemaitre R.N., King I.B., et al. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann. Intern. Med. 2013, 158:515-525.
42. Browning L.M., Walker C.G., Mander A.P., et al. Incorporation of eicosapentaenoic and docosahexaenoic acids in lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am. J. Clin. Nutr. 2012, 96:748-758.
43. Leaf A., Albert C.M., Josephson M., et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005, 112:2762-2768.
44. Rix T.A., Christensen J.H., Schmidt E.B. Omega-3 fatty acids and cardiac arrhythmias. Curr. Opin. Clin. Nutr. Metab. Care 2013, 16:168-173.
45. Harris W.S., Mozaffarian D., Lefevre M., et al. Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J. Nutr. 2009, 139:804S-819S.
46. Kris-Etherton P.M., Harris W.S., Appel L.J. AHA scientific statement: fish consumption, fish oil, omega-3 fatty acids and cardiovascular disease. Circulation 2002, 106:2747-2757.
47. Kris-Etherton P.M., Harris W.S., Appel L.J., for the AHA Nutrition Committee Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 2003, 23:151-152.
48. Maki K.C., Dicklin M.R., Lawless A., Reeves M.S. Omega-3 fatty acids for the treatment of elevated triglycerides. Clin. Lipidol. 2009, 4:425-437.
49. Lovaza (omega-3-acid ethyl esters) capsules, for oral use. Prescribing information. http://https://www.gsksource.com/gskprm/htdocs/documents/LOVAZA-PI-PIL.PDF.
50. Maki K.C., Bays H.E., Dicklin M.R. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J. Clin. Lipidol. 2012, 6:413-426.
51. Saito Y., Yokoyama M., Origasa H., JELIS Investigators, Japan, et al. Effects of EPA on coronary artery disease in hypercholesterolemia patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008, 200:135-140.
52. Maki K.C. Fibrates for treatment of the metabolic syndrome. Curr. Atheroscler. Rep. 2004, 6:45-51.
53. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
54. Sacks F.M., Carey V.J., Fruchart J.C. Combination lipid therapy in type 2 diabetes. N. Engl. J. Med. 2010, 363:692-695.
55. Lee M., Saver J.L., Towfighi A., Chow J., Ovbiagele B. Efficacy of fibrates for cardiovasclar risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011, 217:492-498.
56. Harris W.S., von Schacky C., Park Y. Standardizing methods for assessing omega-3 fatty acid biostatus. The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention 2013, 385-398. Nova Science Publishers, Inc., New York. R.K. McNamara (Ed.).
57. Harris W.S., von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease?. Prev. Med. 2004, 39:212-220.
58. von Schacky C. Use of red cell fatty acid profiles as biomarkers in cardiac disease. Biomark. Med. 2009, 3:25-32.
59. Harris W.S. Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Pharmacol. Res. 2007, 55:217-223.
60. Harris W.S. The omega-3 index as a risk factor for coronary heart disease. Am. J. Clin. Nutr. 2008, 87:1997S-2002S.
61. Harris W.S. The omega-3 index: clinical utility for therapeutic intervention. Curr. Cardiol. Rep. 2010, 12:503-508.
62. von Schacky C. Omega-3 fatty acids vs. cardiac disease-the contribution of the omega-3 index. Cell. Mol. Biol. 2011, 56:93-101.
63. Harris W.S. The omega-3 index: from biomarker to risk marker to risk factor. Curr. Atheroscler. Rep. 2009, 11:411-417.
64. Bell J.G., Mackinlay E.E., Dick J.R., Younger I., Lands B., Gilhooly T. Using a fingertip whole blood sample for rapid fatty acid measurement: method validation and correlation with erythrocyte polar lipid compositions in UK subjects. Br. J. Nutr. 2011, 106:1408-1415.
65. Pottala J.V., Garg S., Cohen B.E., Whooley M.A., Harris W.S. Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: the heart and soul study. Circ. Cardiovasc. Qual. Outcomes 2010, 3:406-412.
66. Harris W.S., Pottala J.V., Lacey S.M., Vasan R.S., Larson M.G., Robins S.J. Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the framingham heart study. Atherosclerosis 2012, 225:425-431.
67. Harris W.S., Thomas R.M. Biological variability of blood omega-3 biomarkers. Clin. Biochem. 2010, 43:338-340.
68. Harris W.S., Varvel S.A., Pottala J.V., Warnick G.R., McConnell J.P. Comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: implications for clinical utility. J. Clin. Lipidol. 2013, 7:433-440.
69. Harris W.S., Pottala J.V., Vasan R.S., Larson M.G., Robins S.L. Changes in erythrocyte membrane trans and marine fatty acids between 1999 and 2006 in older americans. J. Nutr. 2012, 142:1297-1303.
70. von Schacky C. Omega-3 Index and cardiovascular health. Nutrients 2014, 6:799-814.
71. von Schacky C. Omega-3 fatty acids in cardiovascular disease-an uphill battle. Prostaglandins Leukot. Essent. Fatty Acids 2015, 92:41-47.
72. Perk J., De Backer G., Gohlke H., European Association for Cardiovascular Prevention & Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG), et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Fifth Joint Task Force of the European Society of Cardiology; European Association of Echocardiography; European Association of Percutaneous Cardiovascular Interventions; European Heart Rhythm Association; Heart Failure Association; European Association for Cardiovascular Prevention & Rehabilitation; European Atherosclerosis Society; International Society of Behavioural Medicine; European Stroke Organisation; European Society of Hypertension; European Association for the Study of Diabetes; European Society of General Practice/Family Medicine; International Diabetes Federation Europe; European Heart Network. Eur. J. Prev. Cardiol. 2012, 19:585-667.
73. Smith S.C., Benjamin E.J., Bonow R.O., et al. World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011, 124:2458-2473.
74. Archer E., Hand G.A., Blair S.N. Validity of U.S. nutritional surveillance: national health and nutrition examination survey caloric energy intake data, 1971-2010. PLoS One 2013, 8:e76632.
75. Harris W.S., Kennedy K.F., O'Keefe J.H., Spertus J.A. Red blood cell fatty acid levels improve GRACE score prediction of 2-yr mortality in patients with myocardial infarction. Int. J. Cardiol. 2013, 168:53-59.
76. Köhler A., Bittner D., Löw A., von Schacky C. Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index. Br. J. Nutr. 2010, 104:729-736.
77. Madden J., Williams C.M., Calder P.C., et al. The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased fish oil fatty acids intakes. Annu. Rev. Nutr. 2011, 31:203-234.
78. Muhlhausler B.S., Gibson R.A., Yelland L.N., Makrides M. Heterogeneity in cord blood DHA concentration: Towards an explanation. Prostaglandins Leukot. Essent. Fatty Acids 2014, 91:135-140.
79. Schuchardt J.P., Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 2013, 89:1-8.
80. Sublette M.E., Ellis S.P., Geant A.L., Mann J.J. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J. Clin. Psychiatry 2011, 72:1577-1584.
81. Stonehouse W., Conlon C.A., Podd J., et al. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am. J. Clin. Nutr. 2013, 97:1134-1143.
82. Witte A.V., Kerti L., Hermannstädter H.M., et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb. Cortex 2014, 24:3059-3068.
83. Tan Z.S., Harris W.S., Beiser A.S., et al. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology 2012, 78:658-664.
84. Yaqoob P., Pala H.S., Cortina-Borja M., Newsholme E.A., Calder P.C. Encapsulated fish oil enriched in α-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions. Eur. J. Clin. Investig. 2000, 30:260-274.
85. Skinner E.R., Watt C., Besson J.A., Best P.V. Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 1993, 116:717-725.
86. Makrides M., Neumann M.A., Byard R.W., Simmer K., Gibson R.A. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am. J. Clin. Nutr. 1994, 60:189-194.
87. Anderson R.E. Lipids of ocular tissues. IV. A comparison of the phospholipids from the retina of six mammalian species. Exp. Eye Res. 1970, 10:339-344.
88. Sands S.A., Reid K.J., Windsor S.L., Harris W.S. The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytes. Lipids 2005, 40:343-347.
89. von Schacky C., Fischer S., Weber P.C. Long term effects of dietary marine -3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J. Clin. Investig. 1985, 76:1626-1631.
90. Harris W.S., Windsor S.L., Dujovne C.A. Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. J. Am. Coll. Nutr. 1991, 10:220-227.
91. Blonk M.C., Bilo H.J., Popp-Snijders C., Mulder C., Donker A.J. Dose-response effects of fish oil supplementation in healthy volunteers. Am. J. Clin. Nutr. 1990, 52:120-127.
92. Katan M.B., Deslypere J.P., van Birgelen A.P., Penders M., Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes and adipose tissue: an 18 month controlled study. J. Lipid Res. 1997, 38:2012-2022.
93. Rees D., Miles E.A., Banerjee T., et al. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am. J. Clin. Nutr. 2006, 83:331-342.
94. Faber J., Berkhout M., Vos A.P., et al. Supplementation with a fish oil-enriched, high-protein medical food leads to rapid incorporation of EPA into white blood cells and modulates immune responses within one week in healthy men and women. J. Nutr. 2011, 141:964-970.
95. Popp-Snijders C., Schouten J.A., van Blitterswijk W.J., van der Veen E.A. Changes in membrane lipid composition of human erythrocytes after dietary supplementation of (n-3) fatty acids: maintenance of membrane fluidity. Biochim. Biophys. Acta 1986, 854:31-37.
96. Sanders T.A., Roshanai F. The influence of different types of omega 3 polyunsaturated fatty acids on blood lipids and platelet function in healthy volunteers. Clin. Sci. 1983, 64:91-99.
97. Healy D.A., Wallace F.A., Miles E.A., Calder P.C., Newsholme P. The effect of low to moderate amounts of dietary fish oil on neutrophil lipid composition and function. Lipids 2000, 35:763-768.
98. Sperling R.I., Benincaso A.I., Knoell C.T., Larkin J.K., Austen K.F., Robinson D.R. Dietary omega-3 polyunsaturated fatty acids inhibit phosphoinositide formation, and chemotaxis in neutrophils. J. Clin. Investig. 1993, 91:651-660.
99. McGlory C., Galloway S.D., Hamilton D.L., et al. Temporal changes in human skeletal muscle and blood lipid composition with fish oil supplementation. Prostaglandins Leukot. Essent. Fatty Acids 2014, 90:199-206.
100. Harris W.S., Sands S.A., Windsor S.L., et al. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation 2004, 110:1645-1649.
101. Hillier K., Jewell R., Dorrell L., Smith C.L. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991, 32:1151-1155.
102. Sorensen L.S., Rasmussen H.H., Aardestrup I.V., et al. Rapid incorporation of ω-3 fatty acids into colonic tissue after oral supplementation in patients with colorectal cancer: a randomized, placebo-controlled intervention trial. J. Parenter. Enter. Nutr. 2014, 38:617-624.
103. Gurzell E.A., Wiesinger J.A., Morkam C., Hemmrich S., Harris W.S. Is the omega-3 index a valid marker of intestinal membrane phospholipid EPA+DHA content?. Prostaglandin Leukot. Essent. Fatty Acids 2014, 91:87-96.
104. Caslake M.J., Miles E.A., Kofler B.M., et al. Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. Am. J. Clin. Nutr. 2008, 88:618-629.
105. Walker C.G., Browning L.M., Mander A.P., et al. Age and sex differences in the incorporation of EPA and DHA into plasma fractions, cells and adipose tissue in humans. Br. J. Nutr. 2014, 111:679-689.
106. Browning L.M., Walker C.G., Mander A.P., et al. Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans. J. Nutr. 2014, 144:667-672.
107. Walker C.G., West A.L., Browning L.M., et al. The Pattern of fatty acids displaced by EPA and DHA following 12 months supplementation varies between blood cell and plasma fractions. Nutrients 2015, 7:6281-6293.